EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD)

Nicholas M Allen, Mark O'Rahelly, Bruno Eymard, Mondher Chouchane, Andreas Hahn, Gerry Kearns, Dae-Seong Kim, Shin Yun Byun, Cam-Tu Emilie Nguyen, Ulrike Schara-Schmidt, Heike Kölbel, Adela Della Marina und 35 weitere

Brain · 2023

DOI: 10.1093/brain/awad153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2023. Verfasst von Nicholas M Allen und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, School of Medicine, University of Galway, Galway H91 V4AY, Ireland. Hauptthemen laut MEDLINE: Myasthenia Gravis, Neuromuscular Diseases, Arthrogryposis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Miguel Servet, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In utero exposure to maternal antibodies targeting the fetal acetylcholine receptor isoform (fAChR) can impair fetal movement, leading to arthrogryposis multiplex congenita (AMC). Fetal AChR antibodies have also been implicated in apparently rare, milder myopathic presentations termed fetal acetylcholine receptor inactivation syndrome (FARIS). The full spectrum associated with fAChR antibodies is still poorly understood. Moreover, since some mothers have no myasthenic symptoms, the condition is likely underreported, resulting in failure to implement effective preventive strategies. Here we report clinical and immunological data from a multicentre cohort (n = 46 cases) associated with maternal fAChR antibodies, including 29 novel and 17 previously reported with novel follow-up data. Remarkably, in 50% of mothers there was no previously established myasthenia gravis (MG) diagnosis. All mothers (n = 30) had AChR antibodies and, when tested, binding to fAChR was often much greater than that to the adult AChR isoform. Offspring death occurred in 11/46 (23.9%) cases, mainly antenatally due to termination of pregnancy prompted by severe AMC (7/46, 15.2%), or during early infancy, mainly from respiratory failure (4/46, 8.7%). Weakness, contractures, bulbar and respiratory involvement were prominent early in life, but improved gradually over time. Facial (25/34; 73.5%) and variable peripheral weakness (14/32; 43.8%), velopharyngeal insufficiency (18/24; 75%) and feeding difficulties (16/36; 44.4%) were the most common sequelae in long-term survivors. Other unexpected features included hearing loss (12/32; 37.5%), diaphragmatic paresis (5/35; 14.3%), CNS involvement (7/40; 17.5%) and pyloric stenosis (3/37; 8.1%). Oral salbutamol used empirically in 16/37 (43.2%) offspring resulted in symptom improvement in 13/16 (81.3%). Combining our series with all previously published cases, we identified 21/85 mothers treated with variable combinations of immunotherapies (corticosteroids/intravenous immunoglobulin/plasmapheresis) during pregnancy either for maternal MG symptom control (12/21 cases) or for fetal protection (9/21 cases). Compared to untreated pregnancies (64/85), maternal treatment resulted in a significant reduction in offspring deaths (P < 0.05) and other complications, with treatment approaches involving intravenous immunoglobulin/ plasmapheresis administered early in pregnancy most effective. We conclude that presentations due to in utero exposure to maternal (fetal) AChR antibodies are more common than currently recognized and may mimic a wide range of neuromuscular disorders. Considering the wide clinical spectrum and likely diversity of underlying mechanisms, we propose ‘fetal acetylcholine receptor antibody-related disorders’ (FARAD) as the most accurate term for these presentations. FARAD is vitally important to recognize, to institute appropriate management strategies for affected offspring and to improve outcomes in future pregnancies. Oral salbutamol is a symptomatic treatment option in survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisNeuromuscular DiseasesArthrogryposisPregnancyFemaleAdultHumansImmunoglobulins, IntravenousReceptors, CholinergicAutoantibodies

Stichwörter der Autor:innen

arthrogryposis multiplex congenitacongenital myopathyfetal acetylcholine receptor inactivation syndromemyasthenia gravissalbutamoltransient neonatal myasthenia gravis

Substanzen

Immunoglobulins, IntravenousReceptors, CholinergicAutoantibodies

Autor:innen und Institutionen

  • Department of Paediatrics, School of Medicine, University of Galway, Galway H91 V4AY, Ireland.
  • Centre de référence des maladies neuromusculaires Nord/Est/Ile-de-France, Unité Pathologie Neuromusculaire, Bâtiment Babinski, G.H. Pitie-Salpetriere, 75013 Paris, France.
  • Department of Pediatrics, Centre Hospitalier Universitaire de Dijon, Dijon, France.
  • Department of Child Neurology, University Hospital Giessen, 35392 Giessen, Germany.
  • Department of Maxillofacial Surgery, St. James Hospital, Dublin D08 NHY1, Ireland.
  • Department of Neurology, Pusan National University, School of Medicine, Pusan 50612, South Korea.

ORCID-Profile: Cornelia Kornblum, Kristl G Claeys

Förderung

  • Miguel Servet
  • Instituto de Salud Carlos III

Zitieren

APA

Allen, N. M., O'Rahelly, M., Eymard, B., Chouchane, M., Hahn, A., Kearns, G., Kim, D. S., Byun, S. Y., Nguyen, C. E., Schara-Schmidt, U., Kölbel, H., Marina, A. D., Schneider-Gold, C., Roefke, K., Thieme, A., Van den Bergh, P., Avalos, G., Álvarez-Velasco, R., Natera-de Benito, D., …, & Jungbluth, H. (2023). The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD). Brain. https://doi.org/10.1093/brain/awad153

Vancouver

Allen NM, O'Rahelly M, Eymard B, Chouchane M, Hahn A, Kearns G, et al. The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD). Brain. 2023. doi:10.1093/brain/awad153

BibTeX
@article{Allen2023,
  author = {Allen, Nicholas M and O'Rahelly, Mark and Eymard, Bruno and Chouchane, Mondher and Hahn, Andreas and Kearns, Gerry and Kim, Dae-Seong and Byun, Shin Yun and Nguyen, Cam-Tu Emilie and Schara-Schmidt, Ulrike and Kölbel, Heike and Marina, Adela Della and Schneider-Gold, Christiane and Roefke, Kathryn and Thieme, Andrea and Van den Bergh, Peter and Avalos, Gloria and Álvarez-Velasco, Rodrigo and Natera-de Benito, Daniel and Cheng, Man Hin Mark and Chan, Wing Ki and Wan, Hoi Shan and Thomas, Mary Ann and Borch, Lauren and Lauzon, Julie and Kornblum, Cornelia and Reimann, Jens and Mueller, Andreas and Kuntzer, Thierry and Norwood, Fiona and Ramdas, Sithara and Jacobson, Leslie W and Jie, Xiaobo and Fernandez-Garcia, Miguel A and Wraige, Elizabeth and Lim, Ming and Lin, Jean Pierre and Claeys, Kristl G and Aktas, Selma and Oskoui, Maryam and Hacohen, Yael and Masud, Ameneh and Leite, M Isabel and Palace, Jacqueline and De Vivo, Darryl and Vincent, Angela and Jungbluth, Heinz},
  title = {The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD)},
  journal = {Brain},
  year = {2023},
  doi = {10.1093/brain/awad153}
}
Kostenlos starten →